ATE550031T1 - Zusammensetzungen und verfahren für die lipomodellierung - Google Patents
Zusammensetzungen und verfahren für die lipomodellierungInfo
- Publication number
- ATE550031T1 ATE550031T1 AT06772251T AT06772251T ATE550031T1 AT E550031 T1 ATE550031 T1 AT E550031T1 AT 06772251 T AT06772251 T AT 06772251T AT 06772251 T AT06772251 T AT 06772251T AT E550031 T1 ATE550031 T1 AT E550031T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- administering
- fat
- proximally
- lipomodeling
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2271—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Polymerisation Methods In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68827105P | 2005-06-06 | 2005-06-06 | |
PCT/US2006/021873 WO2006133160A2 (en) | 2005-06-06 | 2006-06-06 | Compositions and methods for lipo modeling |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE550031T1 true ATE550031T1 (de) | 2012-04-15 |
Family
ID=37075271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06772251T ATE550031T1 (de) | 2005-06-06 | 2006-06-06 | Zusammensetzungen und verfahren für die lipomodellierung |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090317376A1 (de) |
EP (2) | EP2356997A1 (de) |
AT (1) | ATE550031T1 (de) |
AU (1) | AU2006255097B2 (de) |
CA (1) | CA2610022A1 (de) |
HK (1) | HK1118445A1 (de) |
WO (1) | WO2006133160A2 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060127468A1 (en) | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
US8242294B2 (en) | 2007-06-19 | 2012-08-14 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
AU2008265721B2 (en) * | 2007-06-19 | 2014-03-20 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid composition, method, and preparation |
US20080318870A1 (en) | 2007-06-19 | 2008-12-25 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
JOP20180077A1 (ar) | 2007-06-19 | 2019-01-30 | Kythera Biopharmaceuticals Inc | تركيبات وطرق لحمض صفراوي تخليقي |
US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
ES2829971T3 (es) | 2008-09-02 | 2021-06-02 | Tautona Group Lp | Hilos de ácido hialurónico y/o derivados de los mismos, métodos para fabricar los mismos y usos de los mismos |
US9308070B2 (en) | 2008-12-15 | 2016-04-12 | Allergan, Inc. | Pliable silk medical device |
CN102341109A (zh) * | 2009-03-02 | 2012-02-01 | 多丽丝·赫克斯塞尔 | 医学美容脂肪萎缩 |
US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
US20100249924A1 (en) | 2009-03-27 | 2010-09-30 | Allergan, Inc. | Bioerodible matrix for tissue involvement |
US8420077B2 (en) | 2009-04-20 | 2013-04-16 | Allergan, Inc. | Silk fibroin hydrogels and uses thereof |
US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
PL2550027T5 (pl) | 2010-03-22 | 2019-07-31 | Allergan, Inc. | Polisacharydowe i białkowo-polisacharydowe usieciowane hydrożele do powiększania tkanek miękkich |
WO2012021133A1 (en) | 2010-08-12 | 2012-02-16 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
US8926963B2 (en) | 2010-08-19 | 2015-01-06 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8900571B2 (en) | 2010-08-19 | 2014-12-02 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
EP2605762A1 (de) | 2010-08-19 | 2013-06-26 | Allergan, Inc. | Zusammensetzunge mit fettgewebe und einem pge2-analog sowie ihre verwendung zur behandlung einer weichgewebeerkrankung |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8741281B2 (en) | 2010-08-19 | 2014-06-03 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8894992B2 (en) | 2010-08-19 | 2014-11-25 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
MX363465B (es) | 2011-02-18 | 2019-03-25 | Kythera Biopharmaceuticals Inc | Tratamiento de la grasa submental. |
US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
AU2012262047A1 (en) | 2011-06-03 | 2014-01-16 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
SI2561876T1 (sl) | 2011-08-23 | 2014-08-29 | Kythera Biopharmaceuticals, Inc. | Formulacije deoksiholne kisline in njenih soli |
IN2014CN02188A (de) | 2011-08-23 | 2015-05-29 | Kythera Biopharmaceuticals Inc | |
US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
JP5186050B1 (ja) * | 2012-02-24 | 2013-04-17 | 謙輔 山川 | 皮下組織および皮下脂肪組織増加促進用組成物 |
EP3200838B1 (de) | 2014-09-30 | 2019-09-18 | Allergan Industrie, SAS | Stabile hydrogelzusammensetzungen mit additiven |
CA3003746A1 (en) | 2015-11-04 | 2017-05-11 | Kythera Biopharmaceuticals, Inc. | Treatments of accumulated fat with deoxycholic acid and salts thereof |
CN115135352A (zh) * | 2020-02-18 | 2022-09-30 | 阿皮克斯医疗股份有限公司 | 用于在医疗过程中感知和辨别脂肪和肌肉组织的装置、系统和方法 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4070347A (en) | 1976-08-16 | 1978-01-24 | Alza Corporation | Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality |
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US4600710A (en) | 1985-03-14 | 1986-07-15 | G. D. Searle & Co. | β-Adrenergic receptor agonist alkylaminoalkyl pyridinemethanol derivatives |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5063507A (en) | 1990-09-14 | 1991-11-05 | Plains Cotton Cooperative Association | Goods database employing electronic title or documentary-type title |
US6503277B2 (en) | 1991-08-12 | 2003-01-07 | Peter M. Bonutti | Method of transplanting human body tissue |
CA2474701C (en) | 1993-11-19 | 2009-01-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradeable microparticles containing a biologically active agent |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5545549A (en) * | 1994-02-03 | 1996-08-13 | Synaptic Pharmaceutical Corporation | DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof |
US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
US5602024A (en) * | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
CA2220399A1 (en) | 1995-05-10 | 1996-11-14 | Pfizer Inc. | .beta.-adrenergic agonists |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
FR2754709B1 (fr) * | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
US5998458A (en) | 1997-06-25 | 1999-12-07 | University Technology Corporation | Method of treating heart failure |
IL129951A0 (en) * | 1997-07-02 | 2000-02-29 | Euro Celtique Sa | Prolonged anesthesia in joints and body spaces |
US20050107327A1 (en) * | 1997-12-19 | 2005-05-19 | Hormos Medical Corporation | Method for reducing overproduction of neuropeptide Y in an individual |
US6017879A (en) | 1998-04-03 | 2000-01-25 | B.M.R.A. Corporation B.V. | Template associated NPY Y2-receptor agonists |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
WO2000041671A2 (en) | 1999-01-12 | 2000-07-20 | T & T Pharmaceuticals, Ltd. | Composition, device, and method for subcutaneous fat removal |
US20010041708A1 (en) | 2000-02-15 | 2001-11-15 | Zen-Bio, Inc. | Compositions for preventing cellulite in mammalian skin |
JP4101053B2 (ja) | 2000-08-10 | 2008-06-11 | 田辺三菱製薬株式会社 | プロリン誘導体及びその医薬用途 |
CA2424964C (en) | 2000-10-06 | 2007-12-04 | Tanabe Seiyaku Co., Ltd. | Nitrogen-containing 5-membered ring compound |
TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
JPWO2002051836A1 (ja) | 2000-12-27 | 2004-04-22 | 協和醗酵工業株式会社 | ジペプチジルペプチダーゼ−iv阻害剤 |
US20030022856A1 (en) | 2001-01-30 | 2003-01-30 | The Regents Of The University Of Michigan | Method for sustained release local delivery of drugs for ablation of unwanted tissue |
ATE366724T1 (de) | 2001-02-02 | 2007-08-15 | Takeda Pharmaceutical | Kondensierte heterocyclische derivate |
EP1236723A1 (de) | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamid-Derivate verwendbar als Beta3 Agonisten und ihre pharmazeutischen Anwendungen |
AU2002306823B2 (en) | 2001-03-27 | 2006-05-11 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
SE0103476D0 (sv) | 2001-10-18 | 2001-10-18 | Markus Heilig | New use |
DE60304911D1 (de) | 2002-02-25 | 2006-06-08 | Eisai Co Ltd | Xanthin-Derivate als DPP-IV-Inhibitoren |
US7160551B2 (en) * | 2002-07-09 | 2007-01-09 | The Board Of Trustees Of The University Of Illinois | Injectable system for controlled drug delivery |
US20040185069A1 (en) | 2003-03-22 | 2004-09-23 | Gupta Shyam K. | Hydroxycitric acid derivatives for body slimming and tone firming compositions |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
US7186692B2 (en) | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
WO2004091540A2 (en) | 2003-04-15 | 2004-10-28 | Theraquest Biosciences, Llc | Methods of treating pain and compositions for use therefor |
US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
EP1624882A2 (de) | 2003-05-14 | 2006-02-15 | Emisphere Technologies, Inc. | Zusammensetzungen zur abgabe von peptid yy und pyy agonisten |
US20050065616A1 (en) | 2003-08-08 | 2005-03-24 | Contura Sa | Implantable hydrogel with resorbable shell for use as an endoprothesis |
US7317025B2 (en) | 2003-09-24 | 2008-01-08 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Non-peptidic NPY Y2 receptor inhibitors |
US20050089555A1 (en) | 2003-10-24 | 2005-04-28 | Aventis Pharma Deutschland Gmbh | Medicinal targeted local lipolysis |
US7776815B2 (en) * | 2004-02-24 | 2010-08-17 | Wisconsin Alumni Research Foundation | Use of neuropeptides for ligament healing |
-
2006
- 2006-06-06 WO PCT/US2006/021873 patent/WO2006133160A2/en active Application Filing
- 2006-06-06 AT AT06772251T patent/ATE550031T1/de active
- 2006-06-06 EP EP11154066A patent/EP2356997A1/de not_active Withdrawn
- 2006-06-06 CA CA002610022A patent/CA2610022A1/en not_active Abandoned
- 2006-06-06 US US11/921,594 patent/US20090317376A1/en not_active Abandoned
- 2006-06-06 AU AU2006255097A patent/AU2006255097B2/en not_active Ceased
- 2006-06-06 EP EP06772251A patent/EP1888101B1/de not_active Not-in-force
-
2008
- 2008-08-19 HK HK08109264.2A patent/HK1118445A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2006255097A1 (en) | 2006-12-14 |
AU2006255097B2 (en) | 2012-02-09 |
HK1118445A1 (en) | 2009-02-13 |
WO2006133160A2 (en) | 2006-12-14 |
US20090317376A1 (en) | 2009-12-24 |
EP1888101B1 (de) | 2012-03-21 |
CA2610022A1 (en) | 2006-12-14 |
EP2356997A1 (de) | 2011-08-17 |
EP1888101A2 (de) | 2008-02-20 |
WO2006133160A3 (en) | 2007-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE550031T1 (de) | Zusammensetzungen und verfahren für die lipomodellierung | |
ATE486860T1 (de) | Phenothiazin-derivat zur wundheilung | |
DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
EP2177224A3 (de) | Mittel zur Vorbeugung und Behandlung von Erkrankungen mit RyR-Rezeptormodulation | |
CO6331340A2 (es) | Pirrolo-pirimidinas y pirrolo piridinas | |
ECSP066717A (es) | Compuestos de quinolina sustituidos | |
TW200638934A (en) | Heteroaryl compounds as P2Y1 receptor inhibitors | |
ATE485269T1 (de) | C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden | |
NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
TW200602031A (en) | Antiinflammatory and pain-relieving agent for external, use | |
ECSP067121A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
GEP20084519B (en) | 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors | |
CR20170070A (es) | Composición, método y preparación del ácido biliar sintético | |
ECSP066770A (es) | Nuevos ésteres de quinuclidina cuaternizados | |
EA200701995A1 (ru) | Способы уменьшения кальцификации | |
DE602006020871D1 (de) | Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden | |
TW200616621A (en) | Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | |
ECSP088527A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
AR052071A1 (es) | Procedimientos para modular las actividades del receptor nicotinico alfa 7 de acetilcolina | |
MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
NZ594698A (en) | Method and means for producing tissues and tissues obtained | |
ATE450256T1 (de) | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen | |
ATE432275T1 (de) | Pyrrol- bzw. imidazolamide zur behandlung von obesitas | |
UY28247A1 (es) | Compuestos de benzopirano para uso en el tratamiento y la prevención de afecciones relacionadas con la inflamación. | |
DE602005013287D1 (de) | Zusammensetzung zur behandlung von leder |